T2 Biosystems (NASDAQ:TTOO) PT Lowered to $3.00 at Canaccord Genuity Group

T2 Biosystems (NASDAQ:TTOO) had its price target reduced by Canaccord Genuity Group from $12.00 to $3.00 in a research report sent to investors on Monday morning, Benzinga reports. Canaccord Genuity Group currently has a hold rating on the medical equipment provider’s stock.

T2 Biosystems Trading Down 10.3 %

Shares of NASDAQ:TTOO opened at $3.01 on Monday. The business has a fifty day simple moving average of $3.66 and a 200 day simple moving average of $4.46. T2 Biosystems has a 1 year low of $2.60 and a 1 year high of $70.00.

Institutional Trading of T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Patriot Financial Group Insurance Agency LLC bought a new position in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 127,234 shares of the medical equipment provider’s stock, valued at approximately $28,000. Patriot Financial Group Insurance Agency LLC owned 3.81% of T2 Biosystems at the end of the most recent quarter. 23.18% of the stock is currently owned by institutional investors.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.